The ACST chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACST chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ACST stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ACST Detailed Price Forecast - CNN Money||View ACST Detailed Summary - Google Finance|
|View ACST Detailed Summary - Yahoo! Finance||View ACST Stock Research & Analysis - Zacks.com|
|View ACST Trends & Analysis - Trade-Ideas||View ACST Major Holders - Barrons|
|View ACST Call Transcripts - NASDAQ||View ACST Breaking News & Analysis - Seeking Alpha|
|View ACST Annual Report - CompanySpotlight.com||View ACST OTC Short Report - OTCShortReport.com|
|View ACST Fundamentals - TradeKing||View ACST SEC Filings - Bar Chart|
|View Historical Prices for ACST - The WSJ||View Performance/Total Return for ACST - Morningstar|
|View the Analyst Estimates for ACST - MarketWatch||View the Earnings History for ACST - CNBC|
|View the ACST Earnings - StockMarketWatch||View ACST Buy or Sell Recommendations - MacroAxis|
|View the ACST Bullish Patterns - American Bulls||View ACST Short Pain Metrics - ShortPainBot.com|
|View ACST Stock Mentions - StockTwits||View ACST Stock Mentions - PennyStockTweets|
|View ACST Stock Mentions - Twitter||View ACST Investment Forum News - Investor Hub|
|View ACST Stock Mentions - Yahoo! Message Board||View ACST Stock Mentions - Seeking Alpha|
|View Insider Transactions for ACST - SECform4.com||View Insider Transactions for ACST - Insider Cow|
|View ACST Major Holdings Summary - CNBC||View Insider Disclosure for ACST - OTC Markets|
|View Insider Transactions for ACST - Yahoo! Finance||View Institutional Holdings for ACST - NASDAQ|
|View ACST Stock Insight & Charts - FinViz.com||View ACST Investment Charts - StockCharts.com|
|View ACST Stock Overview & Charts - BarChart||View ACST User Generated Charts - Trading View|
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2019
Posted on Tuesday August 14, 2018
LAVAL, QUÉBEC, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the first quarter ending June 30, 2018. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “Our two TRILOGY Phase 3 studies remain on track to complete enrollment this year. “We have nearly completed the manufacturing of all of the clinical trial materials needed for TRILOGY, and have further diversified our supply of raw krill oil by having completed the validation of a new supplier.
Acasti: 2Q Earnings Snapshot
Posted on Tuesday August 14, 2018
The Laval, Quebec-based company said it had a loss of 18 cents per share. The company's shares closed at 47 cents. A year ago, they were trading at $1.33. _____ This story was generated by Automated Insights ...
Acasti Pharma Announces Mailing of Management Information Circular and Amendment to Stock Option Plan
Posted on Tuesday July 31, 2018
LAVAL, QUÉBEC, July 31, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced the mailing of its management information circular for the upcoming annual meeting of the shareholders (the “Meeting”) of the Company to be held at 1000 De La Gauchetière Street West, Suite 2100, Montreal, Québec H3B 4W5, Canada, on August 28, 2018 at 10:00 a.m. The Company also announces that, subject to the approval of shareholders at the Meeting, the Board of Directors has amended the Company’s stock option plan (the “Stock Option Plan”) in order to decrease the fixed number of common shares of the Company (“Common Shares”) that may be issued upon the exercise of all options granted under the Stock Option Plan from the previous proposal of 7,325,612 shares, as announced on July 2, 2018, which would have represented 20% of the issued and outstanding Common Shares as of June 27, 2018, to 5,494,209 shares, representing 15% of the issued and outstanding Common Shares as of June 27, 2018.
Benzinga Pro's 5 Stocks To Watch Today
Posted on Tuesday July 24, 2018
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Protalix Biotherapeutics Inc (NYSE: PLX ) stock gained ...